Entractinib, a Tumor Agnostic Therapy, Receives FDA Approval
Rozlytrek is a kinase inhibitor that selectively targets ROS1 and NTRK fusions.
Brian Park, PharmD
Drug Information Specialist https://www.endocrinologyadvisor.com
Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.
